Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Status:
Completed
Trial end date:
2018-07-11
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if an experimental agent, AMN107
(nilotinib), can help to control CML in chronic phase. The safety of this experimental agent
will also be studied.